Results 141 to 150 of about 80,637 (252)

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study. [PDF]

Int J Urol
Ogawa I, Narita T, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Tazawa S, Fujita N, Mikami J, Okamoto T, Yamamoto H, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S.   +17 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. [PDF]

In Vivo
Yanishi M, Matsushita J, Kita A, Mishima T, Kinoshita H.   +4 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Efficacy and Safety of Initial Low-Dose, Extended-Interval Nivolumab Monotherapy in a 91-Year-Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report. [PDF]

Clin Case Rep
Kou D, Yan X, Huang Q, Zhong J, Chen Q, Zhao T, Xu X.   +6 more
europepmc   +1 more source

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

Cancer Science, EarlyView.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, Satoshi Nishiwaki, Ichiro Kinoshita, Tetsuhiro Yoshinami, Chigusa Morizane, Yusuke Sato, Toshio Kubo, Mamoru Ito, Hiroshi Nishihara, Toru Mukohara, Hidekazu Shirota, Ryo Ko, Taro Shibata, Manabu Muto, Noboru Yamamoto   +16 more
wiley   +1 more source

Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up? [PDF]

Transl Cancer Res
Lopes CDH, Spreafico A, Araujo DV.
europepmc   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Erythrocyte Transfusion as an Independent Predictor of Survival but Not Immune-Related Toxicity in Nivolumab-Treated Metastatic NSCLC: A Multicenter Cohort. [PDF]

Medicina (Kaunas)
Fidan MC, Çiçek E, Abbasov H, Guliyev M, Çerme E, Akkaya K, Doğan B, Majidova N, Paçacı B, Türkoğlu E, Ekinci Fidan M, Çelik E, Yılmaz M, Bayoğlu İV, Alan Ö, Demirci NS.   +15 more
europepmc   +1 more source